# PRO-DEX, INC. (PDEX) · Edgar & Edgarette company card

> Pro-Dex (PDEX) grew revenue 16.5% in FY2026 to $78 million, operating margin 16.8% against a 1.2% median for surgical & medical instruments & apparatus, equity 63.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 788920 · fiscal year ended 2026-06-30 · 5 audited years read · [page](https://www.pops4.com/boards/company/PDEX) · [JSON](https://www.pops4.com/boards/company/PDEX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $78M |
| Revenue growth, 1 year | 16.5% |
| Revenue growth per year | 16.5% |
| Operating margin | 16.8% (prior year 16.1%) |
| Net margin | 17.6% |
| Operating cash flow | $7M |
| Capital spending | $483,000 |
| Free cash flow | $7M |
| Cash | $8M |
| Long-term debt | $18M |
| Total assets | $75M |
| Total equity | $48M |
| Equity ÷ assets | 63.9% |
| Return on equity | 28.7% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 8.66 (safe zone)
- Piotroski F: 7 of 9 (solid)
- Beneish M: -1.67 (above the −1.78 line)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative; revenue is hard to predict: its 80% range is ±26%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $77.5M (FY2026), total debt $17.5M. Experience: revenue up 16.5% on the year, up 16.5% a year over 4 years; operating margin 16.8%, up from 16.1%. Soundness: equity 63.9% of assets, return on equity 28.7%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $68.2M and $115.1M next year (method v4.1: its own 6-year record of growth weighed at 63% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $69.6M to $113.0M. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin 16.8% against a 1.2% median; growth 16.5% against 11.6%.

Range logged 2026-09-24, receipt 2e5d3af9b0c96d66, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 4, latest 2026-08-28 ([filing](https://www.sec.gov/Archives/edgar/data/788920/000107997326001196/0001079973-26-001196-index.htm))

## Recent filings

- 8-K · filed 2026-10-30 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/788920/000107997326001415/0001079973-26-001415-index.htm)
- 8-K · filed 2026-10-29 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/788920/000107997326001411/0001079973-26-001411-index.htm)
- 10-Q · filed 2026-10-29 · [filing](https://www.sec.gov/Archives/edgar/data/788920/000107997326001410/0001079973-26-001410-index.htm)
- DEF 14A · filed 2026-10-06 · [filing](https://www.sec.gov/Archives/edgar/data/788920/000107997326001325/0001079973-26-001325-index.htm)
- 8-K · filed 2026-09-18 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/788920/000107997326001261/0001079973-26-001261-index.htm)
- 8-K · filed 2026-09-03 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/788920/000107997326001216/0001079973-26-001216-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000788920.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=788920

## Cite

POPS4, Edgar & Edgarette: PRO-DEX, INC. (PDEX) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/PDEX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.